Kook‐Hwan Oh

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

Brad H. Rovin, Jonathan Barratt, Hiddo J.L. Heerspink et al. · The Lancet · 2023 · 224 citations · Full text

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Hiddo J.L. Heerspink, Jai Radhakrishnan, Charles E. Alpers et al. · The Lancet · 2023 · 203 citations · Full text

Glomerulonephritis, Active-controlled Clinical Trial, Renal Function +9

Environmental Heavy Metal Exposure and Chronic Kidney Disease in the General Population

Nam Hee Kim, Young Youl Hyun, Kyu‐Beck Lee et al. · Journal of Korean Medical Science · 2015 · 187 citations · Full text

Hypertension, Metal Contamination, Medical Geochemistry +20

KNOW-CKD (KoreaN cohort study for Outcome in patients With Chronic Kidney Disease): design and methods

Kook‐Hwan Oh, Sue K. Park, Hayne Cho Park et al. · BMC Nephrology · 2014 · 182 citations · Full text

A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy

Mohit Mathur, Jonathan Barratt, Bobby Chacko et al. · New England Journal of Medicine · 2023 · 166 citations · Full text